Navigation Links
Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
Date:1/10/2011

CAMBRIDGE, Mass. and NEW YORK, Jan. 10, 2011 /PRNewswire/ -- Resolvyx Pharmaceuticals (Resolvyx) and Celtic Therapeutics Holdings L.P. (Celtic Therapeutics), a successor firm to Celtic Pharma, announced today that they have entered into a final agreement under which Celtic Therapeutics has acquired and licensed worldwide rights related to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.  Terms of the deal include upfront consideration, near-term milestone payments, and funding for 100% of future development costs. Resolvyx and Celtic Therapeutics will share proceeds from the future divestiture of RX-10045, including up-front payments, royalties or other revenues.

Under the terms of the agreement, Celtic Therapeutics will acquire and license rights to Resolvyx's RX-10045, in all ophthalmic indications. RX-10045 is scheduled to enter a Phase III randomized, placebo-controlled, multi-center study in 2011. As part of the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx compound in a topical formulation for ophthalmic indications.

Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. Resolvins are shown to be highly potent and efficacious across a broad range of pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvyx will continue to develop Resolvins for non-ophthalmic indications.

Dry eye, one of the most common problems treated by ophthalmologists, and a $1.7 billion global market today, is a chronic, multifactorial disease involving inflammation of the tear ducts and ocular surfaces that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surfaces. RX-10045, a resolvin
'/>"/>

SOURCE Celtic Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Originally discovered ... as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory ... by Senju Pharmaceutical Co., Ltd under the trade ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)...  Today, in final recognition of the Centers for ... 1-800 Contacts is sharing how to keep lens cases ... who do not properly care for their lens cases ... Most contact lens wearers understand the importance ... case is sometimes overlooked.  When proper steps to clean ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... 2011 Cumberland Pharmaceuticals Inc. ... on hospital acute care and gastroenterology markets, today announced that ... has been appointed Chief Financial Officer, effective Tuesday, October 18. ... since April of this year. Mr. Greene ...
... HILL, N.C., Oct. 12, 2011 Cempra Holdings, LLC, ... announced that it has filed a registration statement on ... (SEC) relating to its proposed initial public offering. ... and Company are serving as joint book-running managers for ...
Cached Medicine Technology:Cumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer 2Cumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer 3Cempra Holdings, LLC Files Registration Statement for Proposed Initial Public Offering 2
(Date:8/29/2015)... ... 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of ... will present an educational program titled “Asbestos and Your Health.” , The two and ... open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible ... lives of patients, according to a newly published report. Surviving Mesothelioma has more ... article. , The authors of the new paper focus on several types ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... ... , ... Rio Salado College joined nine educational institutions in Washington ... the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... , MONDAY, Jan. 10 (HealthDay News) -- The ... how to create a vaccine that can protect people against ... that people who were infected with the H1N1 virus and ... against a wide variety of flu strains. The virus ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... path through Rep. Gabrielle Giffords, brain on Saturday will likely ... point how extensive that damage might be. However, doctors ... Arizona congresswoman immediately after the shooting are already encouraged by ...
... is a highly subjective experience. We each have a pain ... A paper in the International Journal of Behavioural and ... pain in research. There are many chronic illnesses and ... because of the subjectivity in a patient,s reporting of their ...
... type of skin cancer. In this paper, Leif Ellisen and ... and p73 in SCC cells, and discovered a feedback loop ... SCC, they found that inhibiting one of these miRs decreased ... highlighting a new potential therapeutic target. , Squamous cell carcinoma ...
... researchers have found that a protein that plays an important ... due to additional mechanisms that cause it to promote atherosclerosis, ... the January issue of the journal Arteriosclerosis, Thrombosis and ... why some antioxidant therapies have not yielded more positive results. ...
... change during the 20th century in England and Wales in ... features in Alcohol and Alcoholism . While deaths ... the early part of the century, the pattern changed so ... lower social classes by the end of the century. ...
Cached Medicine News:Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 2Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 3Health News:While Doctors Are Optimistic, Prognosis for Wounded Congresswoman Is Unclear 4Health News:Does it hurt? 2Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2Health News:Social class and changes in mortality from liver cirrhosis over the 20th Century 2
QC 900 is an assayed quality control material for analyzers measuring hematocrit by electrical conductivity methodologies. It is available in two (2) levels for monitoring analyzer performance at var...
... is an assayed quality control ... measurements of total hemoglobin and ... It is available in three ... performance at varying points within ...
... is an assayed quality control material ... blood gas, electrolyte, metabolite, and CO-Oximeter ... control makes it the ideal choice ... is available in three (3) levels ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Medicine Products: